Clomifeencitraat voor hypogonadale klachten: bijna 10 jaar ervaring

Publication date

2022-03

Authors

Huijben, M.
Lock, M. T W TISNI 0000000388855697

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Hypogonadism, is a worldwide problem among men that causes sexual, physical and mental problems. Clomiphene citrate (CC) is an alternative, off-label therapy, especially for men with an active or future child wish. In this single-center study, 153 men treated with CC for hypogonadism were retrospectively analyzed. Outcome measures included hormonal evaluation, hypogonadal symptoms, metabolic and lipid parameters, safety aspects and side-effects. During treatment, total testosterone increased from 9 to 16 nmol/l, with a biochemical improvement in 89% of the patients. Increased levels of total testosterone held after eight years of treatment. With CC treatment, 74% of patients experienced improvement of hypogonadal symptoms. Low to normal luteinizing hormone before CC treatment was a predictor for better testosterone response. Few, non-serious side-effects were reported during CC therapy. In conclusion, CC is an effective short- and long-term treatment, improving both clinical symptoms and biochemical aspects of male hypogonadism, with few side-effects and good safety aspects.

Keywords

clomiphene citrate, male hypogonadism, testosterone deficiency syndrome, Urology

Citation

Huijben, M & Lock, M W T T 2022, 'Clomifeencitraat voor hypogonadale klachten : bijna 10 jaar ervaring', Tijdschrift voor Urologie, vol. 12, no. 2-3, pp. 29-41. https://doi.org/10.1007/s13629-022-00352-3